Vedolizumab for De Novo Ulcerative Colitis After Kidney Transplantation in a Patient With IgA Nephropathy: A Case Report.

Authors

Monica Cojocaru, Mona Dumbravă, Bogdan Marian Sorohan

Published in

Case reports in transplantation. Volume 2026. Pages 3572812. Epub Jul 14, 2026.

Abstract

De novo inflammatory bowel disease (IBD) is a rare but important cause of diarrhea after kidney transplantation (KT). Experience with newer biological agents in the management of IBD among KT recipients remains limited. Vedolizumab is an α4β7 integrin antagonist that selectively blocks a subset of gastrointestinal-homing lymphocytes, which limits systemic immunosuppression and, compared to other biologic agents or novel molecules, may reduce the risk of overimmunosuppression in the setting of KT. We report the case of a KT recipient with IgA nephropathy as the underlying cause of chronic kidney disease, who developed de novo ulcerative colitis after KT and was successfully treated with vedolizumab without experiencing adverse reactions during the 29 months of follow-up.

PMID:
42454344
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.